NCT02759107View on ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

PHASE1CompletedINTERVENTIONAL

Enrollment

142

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

June 26, 2017

Study Completion Date

June 26, 2017

Conditions

HealthyType 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

DRUG

Dulaglutide

Administered SC

Trial Locations (2)

33143

Miami Research Associates, South Miami

117597

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02759107 - A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Biotech Hunter | Biotech Hunter